The sustained-release formulation of Arofil SR (Choline Theophyllinate) is used to provide continuous therapeutic support for managing chronic respiratory conditions and symptoms related to airflow restriction. The medication is a systemic and prophylactic treatment focused on managing symptoms that interfere with functional stability.

This systemic support is relevant for addressing long-term symptom management in conditions where symptoms may intensify temporarily, such as chronic bronchial asthma and specific manifestations of Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. It is applied in clinical settings marked by recurrent breathing difficulties where long-term support is generally relevant for easing symptoms related to airway restriction.

The support provided addresses symptom clusters that may become intense or disruptive, such as wheezing, chest tightness, and persistent shortness of breath. The sustained therapeutic profile generally supports continuous relief throughout the night, which may assist with managing the frequency of episodic manifestations.

Quick Fact: Relief for Airway Restriction

Domain	Therapeutic Context	Primary Symptom Relief
Chronic Respiratory Disease	Long-term Support (managing chronic control)	Easing shortness of breath and wheezing
Episodic Symptoms	Prophylactic Effect (preventive support)	Managing nocturnal manifestations and chest tightness

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use Arofil SR

Official regulatory information defines the specific populations eligible and non-eligible for Arofil SR (Choline Theophyllinate), based on the documented risks associated with its active ingredient, Theophylline.

---

Contraindications and Restrictions

Population Status	Eligibility Rule
Absolute Contraindications	Use is prohibited in patients with known hypersensitivity to theophylline or other xanthine derivatives, pre-existing tachyarrhythmia, or acute porphyria.
Age-Related Restrictions	The medicine is generally not recommended for infants and young children due to highly variable drug clearance and increased risk of toxicity. Older adults (typically over 60) require close monitoring due to reduced clearance.
Comorbidity Restrictions	Conditional use is imposed for patients with severe hepatic impairment (liver disease) due to decreased clearance, requiring special consideration. Caution is also necessary for patients with unstable epilepsy, severe hypertension, congestive heart failure, or active peptic ulcer disease.
Physiological States	Use during pregnancy and lactation is generally restricted. The drug crosses the placenta and is excreted into breast milk; regulatory documents state use is permitted only if the potential benefit outweighs the documented risk.

---

These eligibility rules structure the official regulatory profile by establishing absolute prohibitions and defining specific circumstances where use is limited or restricted based on physiological capacity and pre-existing conditions.

The official documentation regarding Arofil SR interactions focuses on substances that modify the body's processing of theophylline and those that result in combined physiological effects. These patterns are based strictly on government regulatory findings.

Pharmacokinetic Interactions: Altered Clearance

Interactions that alter the clearance rate of Arofil SR are categorized by their effect on theophylline exposure:

Interaction Type	Effect on Theophylline Concentration	Example Medicines and Substances
Reduced Clearance	Increases Concentration	Cimetidine, Ciprofloxacin, Erythromycin, Oral Contraceptives, Allopurinol (ge 600 mg/day), Alcohol
Increased Clearance	Decreases Concentration	Phenytoin, Phenobarbital, Carbamazepine, Tobacco Smoke, St. John’s Wort

Pharmacodynamic and Substance Restrictions

Co-administration with beta-agonists results in a documented synergistic effect. Theophylline formally antagonizes the effects of adenosine receptor agonists, such as Lexiscan. A heightened risk of ventricular arrhythmias is noted when used with the general anesthetic Halothane.

Official regulatory documents generally advise against combining Arofil SR with other xanthine-containing preparations due to the potential for additive CNS effects. Additionally, reduced theophylline clearance is formally documented in populations with impaired liver function, cardiac failure from any cause, and in the elderly.

Arofil SR (Theophylline) is a multifunctional xanthine derivative that modulates key biological systems, resulting in specific modulations within respiratory system processes.

---

Dual Modulation of Airway Muscle Tone

The mechanism of action for Theophylline involves two distinct yet complementary actions that modify the mechanical tone of bronchial smooth muscle. First, it acts as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, leading to elevated levels of the intracellular messenger cAMP within smooth muscle cells. This cascade initiates a relaxation signal, directly initiating bronchial smooth muscle relaxation. Concurrently, it functions as an antagonist of Adenosine receptors, blocking the natural signals that trigger airway narrowing, which blocks the influence of endogenous constrictive signaling.

---

Genetic Control and Enhanced Respiratory Mechanics

Beyond relaxing the airways, the drug operates at the cellular level by influencing genetic regulation. It influences genetic regulation by activating Histone Deacetylase 2 (HDAC2), which in turn suppresses the transcription of genes responsible for producing pro-inflammatory proteins. Furthermore, the compound modulates systems that lead to enhanced contractility of the diaphragm and respiratory muscles, increasing the contractile force of the diaphragm and other respiratory muscles.

How to Use Arofil SR (Choline Theophyllinate)

The administration of Arofil SR is governed by principles that ensure a consistent, long-term therapeutic concentration of the active component, Theophylline, in the body. The medication is strictly for oral administration as a sustained-release (SR) tablet, a formulation designed to release the drug slowly over an extended period.

Administration and Dosing Protocol

The standard adult dosing schedule begins with an initial daily dose ranging from 300 mg to 400 mg. The subsequent maintenance dose must be individually titrated (adjusted) based on the patient’s clinical response and Theophylline serum concentration measurements. This monitoring is required to maintain drug levels within the narrow therapeutic range, typically 10 to 15 micrograms per milliliter (mcg/mL), with the recommended maximum daily dose generally not exceeding 600 mg.

Timing and Handling

The SR tablet is generally taken either once daily or in divided doses every 12 hours. Consistency is key: the dose must be administered at the same time each day to maintain steady-state drug concentrations. The tablet may be taken with or without food.

Mandatory Procedural Restriction

To preserve the controlled-release mechanism and prevent the rapid absorption of the full dose (known as dose dumping), the sustained-release tablet must be swallowed whole. Guidance indicates that the tablet must not be crushed, broken, or chewed.

Population-Specific Use

For older adults (over 60 years), the total daily dose is typically limited to 400 mg or less. Additionally, patients with conditions known to reduce drug clearance, such as liver or heart impairment, require a lower, adjusted dose due to the prolonged presence of the drug in their system.

Research Evidence / Overview of Studies

Phase 3 Trials: Evaluated Use and Outcomes

Research explored the drug’s characteristics and its proposed biological action. Studies have evaluated the drug for potential use in acute and chronic back pain.

Clinical trials have examined whether this approach may be associated with changes in mobility and pain scores. In these trials, reported adverse events were characterized by researchers. The primary goal of these trials was to assess the measured impact on pain scores over a 12-week period compared to placebo.

The drug was evaluated as a non-opioid option in some studies. Research investigated whether the drug’s administration was associated with changes in the requirement for other pain treatments. Study protocols detailed the timing of administration in the evaluated dosing regimens.

---

Combination Therapy Studies

Research has explored the combination of this drug and a low-dose Nonsteroidal Anti-Inflammatory Drug (NSAID) in individuals experiencing severe pain. Studies evaluated whether the combination was associated with different outcomes in pain control compared to monotherapy.

The findings from these trials assessed the tolerability of adding the drug to an existing low-dose NSAID regimen. Results varied, and some data suggested that the combination was associated with differing average daily pain scores compared to the NSAID alone over a 6-week observation period.

---

Long-Term Data and Follow-up

Clinical trials have examined the occurrence of adverse events over extended periods. Reports indicated that individuals with certain liver conditions were excluded from the evaluated populations. Studies evaluated whether the drug was associated with changes in inflammation markers and nerve function. The drug’s development has been the subject of ongoing research.

Long-term data from trials examined whether the drug’s use was associated with maintaining lower chronic pain scores and changes in quality of life measures. One open-label extension study followed participants for 24 months, with researchers noting a consistent pattern in reported pain scores. The occurrence of adverse events related to the drug has been detailed in several published reviews. Studies reported various outcomes and tolerability measures in the populations evaluated. Research continues to explore the role of this drug in managing musculoskeletal conditions.

Key Studies & References

1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls - NCBI Bookshelf
2. Arofil SR leaflet / Summary of Product Characteristics (SmPC) - Regulator or Manufacturer Document

Common questions about Arofil SR (FAQ)

Q: How long does it usually take to feel the effects of Arofil SR?

A: Arofil SR is engineered as a sustained-release medication to gradually achieve a stable, therapeutic concentration in the bloodstream. Because of this slow-release design, the drug's effects are not immediate. Official documents indicate that it typically takes several days of consistent, regular use for the medicine to reach and maintain its required stable level in the body.

Q: What is the main difference between Arofil SR and the regular Arofil tablet?

A: Arofil SR is a Sustained-Release formulation, meaning the active ingredient is released slowly into the system over an extended time. This contrasts with immediate-release tablets, which release the ingredient all at once. The controlled-release mechanism is designed to maintain stable blood levels, which is why official labeling prohibits crushing or chewing the SR tablet.

Q: Are there any special warnings for people with heart conditions using Arofil SR?

A: Regulatory documents list pre-existing conditions like tachyarrhythmia (a type of irregular heart rhythm) as an absolute contraindication, meaning the drug should not be used. Caution and monitoring are also required for patients with heart impairment, such as congestive heart failure. Official information indicates these conditions may reduce drug clearance, potentially leading to higher concentrations of the medicine in the body.

Q: Can I take vitamins or supplements while using Arofil SR?

A: Official interaction documents specifically list the herbal supplement St. John’s Wort as one that may decrease the amount of Arofil SR in the body. Since various other vitamins, supplements, and herbal products can potentially alter how the drug works, regulatory guidance emphasizes that patients should inform their healthcare provider about all vitamins, supplements, and products they use.

Q: Does Arofil SR have an effect on blood pressure?

A: The official safety profile notes that a serious adverse reaction, particularly at high serum concentrations, is significant hypotension, which is a substantial drop in blood pressure. Regulatory documents note that caution is advised for use in patients with severe hypertension (high blood pressure).

Q: What is the expected duration of effect after taking one tablet of Arofil SR?

A: The sustained-release design is specifically engineered to provide consistent, stable support over an extended timeframe. The dosing schedule is designed for administration once every 24 hours or in divided doses every 12 hours to maintain consistent therapeutic levels.

Q: Why is Arofil SR available only as a sustained-release formulation?

A: The sustained-release (SR) formulation is used because it is essential to maintain a stable and continuous concentration of the active ingredient in the bloodstream. This consistent profile is critical for providing prolonged, stable control of chronic symptoms. Official documents also note that this specific salt structure and SR formulation is designed to optimize digestive tolerance.

Q: Does Arofil SR have a generic alternative available?

A: Yes, the active component of Arofil SR is Choline Theophyllinate, which contains Theophylline. Theophylline is available as a generic sustained-release product from multiple manufacturers.

Q: Can Arofil SR affect my sleep pattern?

A: The official safety profile documents nervous system effects, including insomnia (difficulty sleeping) and restlessness, as commonly reported adverse reactions. These effects can impact a person's sleep pattern.

Q: Is Arofil SR considered a controlled substance?

A: According to regulatory classifications, the active ingredient in Arofil SR, Theophylline, is not listed as a scheduled or controlled substance under the U.S. Controlled Substances Act (CSA).

Q: What if I forget to take a dose of Arofil SR?

A: Official patient information states that a missed dose should typically be skipped, and the next scheduled dose should be taken at the usual time. This information advises not to take two doses simultaneously to compensate for a forgotten dose.

Q: Is Arofil SR a medication for depression or anxiety?

A: The medication is officially classified as a bronchodilator, belonging to the xanthine derivative pharmacological class. Its officially recognized purpose is to provide systemic support for the respiratory system by promoting the relaxation of bronchial airways. Official documents do not list depression or anxiety as labeled indications for the drug.

Q: Is Arofil SR a short-term or long-term treatment option?

A: The sustained-release formulation is primarily intended to provide stable, long-term support for individuals managing chronic conditions. The design of the tablet aims to ensure prolonged control of chronic symptoms by maintaining consistent drug levels in the body over time.

Q: Are there published results from clinical trials for Arofil SR?

A: Yes, regulatory summaries of the drug's development detail that various clinical trials have been performed, including Phase 3 studies, research into combination therapies, and open-label extension studies for long-term follow-up. The data generated from these trials informed the drug's official regulatory profile.

Q: What research is available on Arofil SR use in women?

A: Regulatory documents formally address the use of the medicine during specific physiological states, such as pregnancy and lactation. Official information states that use during these times is generally restricted, and permitted only if the potential benefit is assessed to outweigh the documented risks.

Q: Can people with kidney issues use Arofil SR?

A: Official regulatory information specifically identifies that patients with severe hepatic (liver) or cardiac (heart) impairment require close monitoring and possible dose adjustment due to reduced drug clearance. Official guidance emphasizes the importance of discussing all pre-existing conditions with a healthcare provider.

Q: Are specific lab tests recommended before starting Arofil SR?

A: Official labeling mandates that dose adjustments are guided by blood tests that measure the Theophylline serum concentration after treatment has begun. However, regulatory information does not explicitly mandate specific lab tests before the very first dose is administered.

Q: Is Arofil SR the same as other brands with similar active ingredients?

A: Arofil SR contains the active ingredient Choline Theophyllinate. While this active ingredient may be found in other branded or generic products, it is important to note that different brands can vary in their formulation. Differences often include whether they are sustained-release or immediate-release, as well as variations in inactive ingredients (excipients).

Q: What does the research say about Arofil SR and focus?

A: Official safety documents list nervous system effects like restlessness and tremors, which can affect concentration. Furthermore, studies have examined the relationship between the drug and cognitive effects, with some research suggesting a link to improved scores on laboratory measures of attention in certain pediatric populations.

Q: Are there common substances (like alcohol) that interact negatively with Arofil SR?

A: Yes, official documents explicitly list alcohol as a substance that can reduce the body's clearance of the drug. This effect can lead to an increase in the medicine's concentration in the bloodstream. It is generally advised to avoid or limit the consumption of alcohol while using this medicine.

Q: Do studies mention any impact of Arofil SR on mood?

A: Official safety documents list central nervous system effects such as restlessness and irritability. Some studies have also examined potential emotional and behavioral changes, with some research noting a tendency toward withdrawal in certain pediatric patient groups.

How to Store and Dispose of Arofil SR

Official regulatory information provides specific instructions to ensure the stability and safety of Arofil SR. These instructions must be strictly followed:

Mandatory Storage Conditions

Requirement	Specifics
Temperature	Store in a cool, dry environment, typically below 25 C (or 30 C in some regions).
Protection	The product must be protected from both light and moisture.

Handling and Child Protection

• Child Safety: It is mandatory to keep Arofil SR, like all medicines, out of the reach of children and pets at all times.
• Handling: Keep the medicine in its original container to ensure protection from environmental factors.

Disposal Requirements

Do not dispose of unused or expired Arofil SR by flushing it down a toilet or throwing it in household trash. Official disposal must follow local pharmaceutical waste regulations or take-back programs to protect the environment.